ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,564.41
      1.08%
      US Tech 100
      19,255.20
      1.29%
      Dow Jones
      40,421.36
      0.33%
      Brent Oil
      81.525
      0.01%
      Bitcoin
      67,574.57
      -0.04%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU

      6. OSE Immunotherapeutics (OSE) Quote

      OSE Immunotherapeutics

      OSE Immunotherapeutics (OSE)

      EU
      6.46
      -0.11
      (-1.67%)
      Closed July 22 11:30AM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      6.46
      Bid
      6.45
      Ask
      6.59
      Volume
      59,502
      6.46 Day's Range 6.63
      2.705 52 Week Range 8.63
      Market Cap
      143.014M
      Previous Close
      6.57
      Open
      6.56
      Last Trade
      103
      @
      6.46
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      200,497
      Shares Outstanding
      21,767,777
      Dividend Yield
      -
      PE Ratio
      -6.11
      Earnings Per Share (EPS)
      -1.06
      Revenue
      2.23M
      Net Profit
      -23M

      About OSE Immunotherapeutics

      Sector
      Coml Physical, Biologcl Resh
      Industry
      Coml Physical, Biologcl Resh
      Website
      www.ose-immuno.com
      Headquarters
      Nantes, Loire-atlantique, Fra
      Founded
      1970
      OSE Immunotherapeutics is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker OSE. The last closing price for OSE Immunotherapeutics was 6.57 €. Over the last year, OSE Immunotherapeutics shares have traded in a share price range of 2.705 € to 8.63 €.

      OSE Immunotherapeutics currently has 21,767,777 shares outstanding. The market capitalization of OSE Immunotherapeutics is 143.01 € million. OSE Immunotherapeutics has a price to earnings ratio (PE ratio) of -6.11.

      OSE Latest News

      More News

      OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer

      OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer OSE Immunotherapeutics et...

      July 03 2024
      GlobeNewswire Inc.

      Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

      Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 Boehringer Ingelheim and OSE Immunotherapeutics...

      July 03 2024
      GlobeNewswire Inc.

      Informations relatives au nombre total de droits de vote et d’actions composant le capital

      Informations relatives au nombre total de droits de vote et d’actions composant le capital Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes...

      July 02 2024
      GlobeNewswire Inc.

      OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ 

      OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’  OSE Immunotherapeutics...

      July 01 2024
      GlobeNewswire Inc.

      OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T

      OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T OSE Immunotherapeutics annonce un accord commercial et de partage...

      June 24 2024
      GlobeNewswire Inc.

      OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)

      OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San...

      June 20 2024
      GlobeNewswire Inc.

      OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société

      OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société OSE...

      June 19 2024
      GlobeNewswire Inc.

      OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse

      OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse OSE Immunotherapeutics...

      June 12 2024
      GlobeNewswire Inc.

      Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellules

      Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellules Webinaire KOL...

      June 12 2024
      GlobeNewswire Inc.

      OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

      OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant OSE Immunotherapeutics and Nantes University...

      June 05 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.73-10.15299026437.197.246.461080816.69255229DE
      40.284.530744336576.187.275.371442956.4071998DE
      120.8615.35714285715.68.635.372004976.94179242DE
      262.7172.26666666673.758.633.1151646886.06198294DE
      523.0187.24637681163.458.632.7051850035.3638651DE
      156-2.34-26.59090909098.813.682.705919676.2011084DE
      2602.771.80851063833.7615.82.705849037.20176405DE

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MIRAMIRA Pharmaceuticals Inc
      $ 5.01
      (627.35%)
      		157.94M
      CMAXCareMax Inc
      $ 5.19
      (228.48%)
      		102.61M
      NUKKNukkleus Inc
      $ 0.499
      (55.94%)
      		26.19M
      SNOASonoma Pharmaceuticals Inc
      $ 0.423
      (37.34%)
      		4.87M
      ONDSOndas Holdings Inc
      $ 1.1297
      (34.06%)
      		2.19M
      LGCBLinkage Global Inc
      $ 3.6601
      (-29.82%)
      		168k
      CGBSCrown LNG Holdings Ltd
      $ 0.9997
      (-29.10%)
      		3.38M
      SPECSpectaire Holdings Inc
      $ 0.3962
      (-24.53%)
      		1.87M
      GSUNGolden Sun Health Technology Group Ltd
      $ 5.13
      (-23.66%)
      		158.58k
      PSNLPersonalis Inc
      $ 2.9808
      (-22.58%)
      		3.1M
      NVDANVIDIA Corporation
      $ 123.54
      (4.76%)
      		238.8M
      SQQQProShares UltraPro Short QQQ
      $ 8.09
      (-4.37%)
      		183.24M
      MIRAMIRA Pharmaceuticals Inc
      $ 5.01
      (627.35%)
      		157.94M
      SERVServe Robotics Inc
      $ 8.73
      (15.63%)
      		151.44M
      NCPLNetcapital Inc
      $ 0.1118
      (7.50%)
      		124.21M

      Discussion

      View Full Feed
      bigstocksnbonds bigstocksnbonds 5 minutes ago
      YES SIR!!!!!
      MasterBlastr MasterBlastr 6 minutes ago
      Have to take advantage of the rules of the game, to make it fair.
      bigstocksnbonds bigstocksnbonds 6 minutes ago
      Awesome yes!!!!!
      Real McCoy Real McCoy 6 minutes ago
      If you are going to start the cycle by saying that some folks here are cruelly committed to not allowing complete lies and fantasies to sit unrefuted, I will gladly complete the cycle by noting you are also guilty of an equal committment to fight for the right to say you believe said lies and fantas
      Scott 75 Scott 75 6 minutes ago
      Hopefully not on a cold slab somewhere.
      UATG
      janice shell janice shell 7 minutes ago
      Bobo is just so breathtakingly stupid.
      BADALI BADALI 7 minutes ago
      I am watching this week and will add if goes Lower.
      HIRU
      _-Abe-_ _-Abe-_ 7 minutes ago
      Just remember. This company has a pile of back orders to fill and are now able to begin that process. I’m looking forward to Q4 numbers.
      EOSE
      Genz2 Genz2 8 minutes ago
      https://www.theregister.com/AMP/2024/07/22/windows_crowdstrike_kernel_eu/

      Why is Microsoft blaming the EU when it is apparent that they didn’t allow Wave on Windows 10 and 11? I think they allowed Crowdstrike on their platform because they knew that Clownstrike was inferior to Window
      moosedogger moosedogger 8 minutes ago
      "I won't sell for less than "60.00"

      Prove that you really missed me! I think you are not only FOS but also suffer from excrement of the 11th magnitude clogging what used to be your brain.

      You might be the saddest and mentally sickest creature on the iHub boards.
      AUPH
      irishintelligence irishintelligence 8 minutes ago
      Who knows - it obviously does not matter. Nothing is stopping him from continuing to develop property.


      http://cdn.ceo.ca.s3-us-west-2.amazonaws.com/1dr223l-Anatomy%20of%20a%20Basher%20-%20Do%20and%20Don%27t.pdf

      “Use 10% fact and 90% suggestion”

      Fa
      SPZI
      Gmenfan Gmenfan 9 minutes ago
      Thanks for the heads up Bull. I had to cut the emails off from that site a while ago. They and many others don't know, or don't care, how annoying it is to be inundated with a barrage of unsolicited e-mails! Turns me completely off!
      Chartmaster Chartmaster 9 minutes ago
      NWPN Chart is bottoming, 2021 type potential is creeping back to OTC!

      https://investorshub.advfn.com/uimage/uploads/2024/7/22/bzsctNWPN_7-22-24.PNG
      NWPN
      fuagf fuagf 10 minutes ago
      LOL If i don't relax my LIV ban you will for sure. You'll always have more events than i so it's tougher for you .. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174787016 . Since Rory softened on the question i likely will too. I can't reverse the downward slide with one arm and
      Konaploinks Konaploinks 10 minutes ago
      At least my nvda is back up. My Intel still needs to get the lead out. My Vcsy is still mia. Come on TsC. Rule!
      StockInfo11 StockInfo11 11 minutes ago
      This Wednesday (July 24th) at 11:30 AM Eastern Time, copper jr ZEUS.c will present at the Battery & Precious Metals Virtual Investor Conference. The company is part of the strategic discussions aimed at highlighting advancements and opportunities in the mining sector, particularly within the battery
      ZEUS
      Dano02VFR Dano02VFR 11 minutes ago
      Why is everything "Oh wow" with you?
      ERBB
      blackhawks blackhawks 12 minutes ago
      Like most sweeping generalizations, meritless.

      Mindless trickle down economics AND spending = recessions. Dem response, almost always it's the Dems elected to clean up the f'ing mess....see Great Recession.....of necessity is deficit spending.

      ALL threats of gov shutdow
      hedge_fun hedge_fun 12 minutes ago
      Wouldn’t hand-fanning be more…….

      environmentally friendly than the SeaVac?

      Or is hand-fanning more disturbing?

      It’s a bit hard to tell.

      And speaking of that, do you see a tension between SFRX’s statement on the new website…. BEFORE IT’S TO
      SFRX
      neomania neomania 12 minutes ago
      Going shoulder to knee.
      NSAV
      drhome drhome 12 minutes ago
      Perhaps entitled to have some $ selling some shares to pay some bills. Its been a long road for many years, so I'm sure there's been some hurt financially for Emil. I just wish they wouldn't be dumping shares for so long. That is bound to make any shareholder uncomfortable.
      VPLM
      irishintelligence irishintelligence 13 minutes ago
      http://cdn.ceo.ca.s3-us-west-2.amazonaws.com/1dr223l-Anatomy%20of%20a%20Basher%20-%20Do%20and%20Don%27t.pdf

      This is so good. “Use 10% fact and 90% suggestion”

      Bashers are paid. Check it out.
      SPZI
      wingtrade wingtrade 13 minutes ago
      The stock structure is why the stock is in the low trips. I’m genuinely curious what he means by somehow implying that the SS is good. The only way that makes any sense to me is if transfer all the restricted shares in a change of control, and then new management cancels them all. I’m scratching my
      FUNR

      Your Recent History

      EU
      OSE
      OSE Immunotherapeutics
      NYSE
      PCS
      Sprint Pcs
      Delayed Upgrade Clock